The DOH is starting the call for nominations for HTAC positions. You may refer here: DC No. 2022-0491 for guidance on the submission of nominees and the requirements. The deadline for submission of documents is extended until 07 December 2022. Document preview:
[Department Circular No. 2022 – 0584] Amendment to the Department Circular 2022-0254 dated 05 April 2022 titled, “Updates on the HTAC Processing of Minor Inclusion”
Department Circular 2022-0254 titled “Updates on the HTAC processing of Minor inclusion”: DC No. 2022-0254
HTAC Recommendation on the PNF Inclusion of Remdesivir for Adult Patients with COVID-19 Requiring Hospitalization
On 07 November 2022, the OIC-Secretary of Health (SOH) approved the Health Technology Assessment (HTAC) recommendation for the government financing of remdesivir (100mg lyophilized powder) for adult patients with COVID-19 requiring hospitalization through its inclusion in the Philippine National Formulary (PNF). This HTAC recommendation serves as an update of the interim HTAC recommendation on the procurement and/or continue reading : HTAC Recommendation on the PNF Inclusion of Remdesivir for Adult Patients with COVID-19 Requiring Hospitalization
Evidence brief for 29 October to 04 November 2022
For the period of 29 October 2022 to 04 November 2022 Reviewed by: Department of Health (DOH) – Health Technology Assessment Division (HTAD) Document Link: 29 October – 04 November 2022 Document Preview: